Objectives: To estimate the prevalence of rheumatic disease and related factors in a Colombian population over 18 years of age in six Colombian cities Methods: A Cross-sectional analytical study was designed in people older than 18 years. A probabilistic stratified sampling method using three stages. The first stage of sampling was the selection of cartographic sectors in each city. The second stage of sampling was the blocks of each sector. The third stage of sampling was the homes of each block. All household members were surveyed. The sample size was calculated to be 6,528 people (2336 from Bogotá, 1220 from Medellín and Cali each, 746 from Barranquilla, 503 from Bucaramanga and Cúcuta each). The COPCORD questionnaire adapted for Colombia, was applied in the first stage by standardized interviewers. Positive cases were reviewed at home by a first year rheumatology fellow. To assess whether it is a rheumatic disease; the positive cases for a probable rheumatic disease were reviewed by a second year rheumatology fellow and reviewed again with laboratory and image studies by a certified rheumatologist to establish the definitive diagnosis Results: 3,146 men and 3,547 women were included. Pain in the last 7 days not associated with trauma was reported in 3,213 (48%) participants. The most frequent sites were knees (right 31%, left 29%), hands (right 25%, left 24%), lumbar spine (18%) and shoulders (right 16%, left 14%). Table 1 depicts the prevalence of rheumatic diseases in Colombia
Background: Infection is a complication of biologic therapy in RA. Objectives: To describe the incidence and pattern of serious infection within the British Society for Rheumatology Biologics Register (BSRBR-RA) by drug. Methods: The BSRBR-RA is a prospective observational study designed to evaluate the safety of biologics. Adverse events are coded using MedDRA defintitions. This analysis included patients with RA starting a biologic. They were considered at risk from their start date until 3 half-lives after stopping their biologic, death, first serious infection, or completion of three years of therapy, whichever came first. Event rates were compared across biologics using Cox proportional hazards with adjustment for age, gender, disease severity and duration, smoking, seropositivity, polypharmacy and baseline steroid usage. Background: Anti-TNF alpha treatment may improve endothelial function and mechanical properties of large artery stiffness in patients with inflammatory rheumatic diseases, however studies remain controversial. Objectives: To study the effect of TNF alpha blockage with adalimumab for 24 weeks on brachial endothelial function and sub-clinical markers of atherosclerosis in patients with inflammatory rheumatic diseases. Methods: A total of 26 patients (14 males, 12 females; mean age, 47±11 years) with inflammatory rheumatic diseases (16, rheumatoid arthritis; 9, ankylosing spondylitis, 1, psoriasic rheumatism), resistant to disease-modifying antirheumatic drugs, were studied before the first infusion of adalimumab and again after 24 weeks of treatment. Endothelial function was assessed by measuring flow mediated dilatation using an ultrasound Doppler technique on the brachial artery. Other markers of sub clinical atherosclerosis were assessed by arterial stiffness via aortic pulse wave velocity, augmentation index and central blood pressure, and carotid intima-media thickness. Data for body mass index, disease activity using DAS-PCR and BASDAI, C-reactive protein, fasting glycaemia, and lipid profile were collected before treatment and after 24 weeks. Results: 24 weeks of adalimumab therapy resulted in a reduction of disease activity score and serum levels of C-reactive protein. No significant differences were found in body mass index, total cholesterol, triglycerides and fasting glycaemia. Brachial blood pressure and heart rate remained similar, as well as carotid intima-media thickness. After 24 weeks of treatment with adalimumab, flow mediated dilatation improved significantly; central systolic and diastolic blood pressure decreased significantly; however central pulse pressure, augmentation index and aortic pulse wave velocity remained unchanged. 
